It has been demonstrated that atorvastatin can mitigate EMT in NSCLC, which may be related to its ability to attenuate the upregulation of sphingosine kinase 1 (SphK1) that is induced by TGF‐β1. Here, SPHK1 is linked to non-small cell lung carcinoma.